Case Reports of Serotonin Syndrome Induced by Methylene Blue:A Literature Analysis
Objective To promote the clinical safe use of methylene blue.Methods The case reports related to serotonin syndrome induced by methylene blue in the CBM,VIP,CNKI,WanFang Med Online,PubMed and Embase databases from the inception of each database to May 2023 were searched.The information on patients' gender,age,medication indications,dosage,combined medication,clinical manifestations,intervention measure,recovery and outcome was extracted for descriptive statistical analysis.Results A total of 24 reports were included;24 patients were involved,including 12 males and 12 females,and their age was in the range of 15-77 years in 23 reports,with an average of(55.30±15.67)years.The main medication indication was surgical diagnosis(19 cases,79.17%).The patients were given drugs mainly by intravenous drip with a dosage of 1-2 mg/kg,5-10 mg/kg,50-100 mg/kg or 425 mg(21 cases).The serotonin drugs were often used in combination with antidepressants(19 cases,79.17%).The serotonin syndrome mostly occurred after anesthesia awakening(nine cases,37.50%),and symptoms were more common in limb disorders(20 cases,83.33%).The most common outcome was improvement(22 cases,91.67%),with a median improvement-time of 2 d.Conclusion The serotonin syndrome induced by methylene blue is rare but serious,which often occurs in middle-aged and elderly patients.The risk of this adverse reaction will increase when multiple serotonin drugs are used in combination.When methylene blue is used in combination with other serotonin drugs,the clinical symptoms of patients should be closely monitored.
万方数据
维普
